PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more
PharmaEngine (4162) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, PharmaEngine (4162) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.01 Million) by net assets (NT$4.79 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PharmaEngine - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how PharmaEngine's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PharmaEngine Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaEngine ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Healthco Healthcare and Wellness REIT
AU:HCW
|
0.016x |
|
Goodluck India Limited
NSE:GOODLUCK
|
0.040x |
|
JMT Network Services Public Company Limited
BK:JMT
|
0.024x |
|
Shanghai KEN Tools Co Ltd
SHE:300126
|
-0.029x |
|
Cub Elecparts Inc
TW:2231
|
0.043x |
|
Mildef Crete
TWO:3213
|
0.032x |
|
Liaoning Shidai Wanheng Co Ltd
SHG:600241
|
0.014x |
|
Greenlam Industries Limited
NSE:GREENLAM
|
0.135x |
Annual Cash Flow Conversion Efficiency for PharmaEngine (2009–2024)
The table below shows the annual cash flow conversion efficiency of PharmaEngine from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.40 Billion | NT$456.73 Million | 0.085x | +27.15% |
| 2023-12-31 | NT$3.86 Billion | NT$256.97 Million | 0.067x | +27.51% |
| 2022-12-31 | NT$3.87 Billion | NT$202.01 Million | 0.052x | -77.90% |
| 2021-12-31 | NT$3.94 Billion | NT$929.67 Million | 0.236x | +1361.78% |
| 2020-12-31 | NT$4.01 Billion | NT$64.77 Million | 0.016x | +249.80% |
| 2019-12-31 | NT$3.48 Billion | NT$16.08 Million | 0.005x | -97.71% |
| 2018-12-31 | NT$3.69 Billion | NT$745.23 Million | 0.202x | +332.53% |
| 2017-12-31 | NT$3.91 Billion | NT$-339.30 Million | -0.087x | -137.86% |
| 2016-12-31 | NT$3.80 Billion | NT$870.38 Million | 0.229x | +61.57% |
| 2015-12-31 | NT$3.16 Billion | NT$447.99 Million | 0.142x | +216.59% |
| 2014-12-31 | NT$2.93 Billion | NT$131.09 Million | 0.045x | +357.03% |
| 2013-12-31 | NT$2.72 Billion | NT$-47.37 Million | -0.017x | -141.46% |
| 2012-12-31 | NT$1.63 Billion | NT$68.64 Million | 0.042x | -90.56% |
| 2011-12-31 | NT$618.48 Million | NT$275.49 Million | 0.445x | +163.34% |
| 2010-12-31 | NT$81.42 Million | NT$-57.26 Million | -0.703x | +91.23% |
| 2009-12-31 | NT$11.29 Million | NT$-90.54 Million | -8.018x | -- |